Although increasing clinical evidence has demonstrated beneficial effects of opioid agents in depression, the widespread use of treatments acting as full or partial MOR agonists in MDD has been limited by major concerns regarding the risk of abuse and dependency. Here, OPRM1 is linked to depressive symptom measurement.